Alvotech (ALVO) News Today $11.66 +0.10 (+0.87%) Closing price 04:00 PM EasternExtended Trading$11.67 +0.01 (+0.12%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Royce & Associates LP Buys 28,000 Shares of Alvotech (NASDAQ:ALVO)Royce & Associates LP boosted its stake in Alvotech (NASDAQ:ALVO - Free Report) by 21.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,000 shares of the company's stock after buyingMarch 22 at 4:09 AM | marketbeat.comAlvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D DealMarch 20, 2025 | benzinga.comAlvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003March 20, 2025 | seekingalpha.comAlvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and ProductionMarch 20, 2025 | markets.businessinsider.comAlvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003March 20, 2025 | msn.comAlvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and ProductionMarch 20, 2025 | globenewswire.comAlvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and ProductionMarch 20, 2025 | globenewswire.comAlvotech (NASDAQ:ALVO) Short Interest UpdateAlvotech (NASDAQ:ALVO - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 519,100 shares, an increase of 21.7% from the February 13th total of 426,400 shares. Based on an average trading volume of 162,900 shares, the days-to-cover ratio is presently 3.2 days. Currently, 0.5% of the shares of the company are sold short.March 19, 2025 | marketbeat.comAlvotech (ALVO) Expected to Announce Quarterly Earnings on WednesdayAlvotech (NASDAQ:ALVO) will be releasing earnings after the market closes on Wednesday, March 26, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669439)March 19, 2025 | marketbeat.comDr. Reddy’s, Alvotech announce FDA acceptance of BLA for AVT03March 18, 2025 | msn.comAlvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03March 18, 2025 | msn.comFDA Accepts Alvotech’s BLA for Biosimilar AVT03March 18, 2025 | tipranks.comExploring 3 High Growth Tech Stocks In The US MarketMarch 12, 2025 | finance.yahoo.comAlvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare ...March 7, 2025 | gurufocus.comAlvotech (ALVO) to Participate in Barclays 27th Annual Global Healthcare ConferenceMarch 7, 2025 | gurufocus.comAlvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, FloridaMarch 7, 2025 | globenewswire.comAlvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, FloridaMarch 7, 2025 | globenewswire.comIs Alvotech (ALVO) the Best Low Price Pharma Stock to Invest In Right Now?February 27, 2025 | insidermonkey.comAlvotech Launches SELARSDI Biosimilar in U.S. MarketFebruary 24, 2025 | tipranks.comAlvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ETFebruary 24, 2025 | globenewswire.comTeva Pharma and Alvotech launch biosimilar to J&J's Stelara in USFebruary 23, 2025 | msn.comAlvotech (NASDAQ:ALVO) Shares Up 5.5% - Here's WhyAlvotech (NASDAQ:ALVO) Stock Price Up 5.5% - Here's WhyFebruary 22, 2025 | marketbeat.comTeva, Alvotech announces U.S. availability of SELARSDI injectionFebruary 22, 2025 | markets.businessinsider.comTeva Pharma and Alvotech launch US biosimilar to J&J's StelaraFebruary 21, 2025 | reuters.comTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.February 21, 2025 | financialpost.comTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.February 21, 2025 | financialpost.comTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.February 21, 2025 | globenewswire.comTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.February 21, 2025 | globenewswire.comAlvotech (NASDAQ:ALVO) Stock Price Down 6.7% - Time to Sell?Alvotech (NASDAQ:ALVO) Stock Price Down 6.7% - Should You Sell?February 20, 2025 | marketbeat.comTeva and Alvotech gets FDA review acceptance for its proposed biosimilar to EyleaFebruary 18, 2025 | msn.comFDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's EyleaFebruary 18, 2025 | investopedia.comAlvotech’s AVT06 Biosimilar Application Accepted by FDAFebruary 18, 2025 | tipranks.comAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)February 18, 2025 | globenewswire.comAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)February 18, 2025 | globenewswire.comUBS Group Initiates Coverage on Alvotech (NASDAQ:ALVO)UBS Group started coverage on shares of Alvotech in a research report on Friday. They set a "buy" rating and a $18.00 price target for the company.February 15, 2025 | marketbeat.comUBS Initiates Coverage of Alvotech (ALVO) with Buy RecommendationFebruary 15, 2025 | msn.comAlvotech initiated with a Buy at UBSFebruary 14, 2025 | markets.businessinsider.comUBS maintains Alvotech stock Buy rating, $18 targetFebruary 14, 2025 | msn.comTempus Wealth Planning LLC Buys New Position in Alvotech (NASDAQ:ALVO)Tempus Wealth Planning LLC purchased a new position in Alvotech (NASDAQ:ALVO - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 23,467 shares of the company's stock, valued at approximately $310,000. A number of other large investors alsoFebruary 5, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Shares Gap Down - What's Next?Alvotech (NASDAQ:ALVO) Shares Gap Down - What's Next?February 4, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Sees Unusually-High Trading Volume - Should You Buy?Alvotech (NASDAQ:ALVO) Sees Strong Trading Volume - What's Next?February 3, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Invests $748,000 in Alvotech (NASDAQ:ALVO)China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alvotech (NASDAQ:ALVO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 56,576 shares of the company's stock, valued at approxFebruary 2, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Short Interest Down 12.9% in JanuaryAlvotech (NASDAQ:ALVO - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 380,200 shares, a decrease of 12.9% from the December 31st total of 436,500 shares. Based on an average daily volume of 120,400 shares, the days-to-cover ratio is presently 3.2 days. Currently, 0.4% of the shares of the stock are short sold.February 1, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Shares Gap Up - Here's What HappenedAlvotech (NASDAQ:ALVO) Shares Gap Up - What's Next?January 31, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Sees Significant Growth in Short InterestAlvotech (NASDAQ:ALVO - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 436,500 shares, a growth of 244.2% from the December 31st total of 126,800 shares. Based on an average daily volume of 117,000 shares, the days-to-cover ratio is currently 3.7 days. Approximately 0.4% of the company's stock are short sold.January 28, 2025 | marketbeat.comAlvotech, Teva announce FDA accepts BLA for AVT05January 27, 2025 | markets.businessinsider.comFDA Accepts Alvotech’s Biosimilar Applications for ReviewJanuary 27, 2025 | tipranks.comAlvotech: FDA To Review BLA For AVT05 - Quick FactsJanuary 27, 2025 | markets.businessinsider.comAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi ® and Simponi Aria ® (golimumab)January 27, 2025 | investing.comAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi ® and Simponi Aria ® (golimumab)January 27, 2025 | investing.com Remove Ads Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALVO Media Mentions By Week ALVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALVO News Sentiment▼0.580.68▲Average Medical News Sentiment ALVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALVO Articles This Week▼113▲ALVO Articles Average Week Remove Ads Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today GMAB News Today RDY News Today VTRS News Today ASND News Today PCVX News Today QGEN News Today ROIV News Today SRPT News Today RVMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALVO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALVO Stock Free ALVO Stock Alerts